# Aeonvital

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aeonvital

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.aeonvital.com
- Latest round: Series A (Aug 21, 2025)
- Investors on record: 2

## About

Founded in 2021 and based in Bejing, China, Aeonvital operates as a developer of novel individualized tumor immunotherapy products, dedicated to the development of novel individualized tumor immunotherapy products. In August 2021, the company raised angel funding from Jintan Investment. In June 2022, It closed pre-series A funding from new investor Tamon Investment Fund Management (Beijing). In August 2025, Aeonvital raised an undisclosed amount of series A funding from new investors Yuanzhilifan Investment Management and JC Capital.

The company has two core technology platforms. The first is a cell therapy development platform for TILs for solid tumors, and the second is a therapeutic nucleic acid vaccine development platform for precancerous lesions caused by HPV infection and cervical cancer. The first product developed through the TIL cell therapy development platform has completed all preclinical studies and is about to undergo IND filing. The company generates revenue from offering novel individualized tumor immunotherapy products.

The new financing will help the company further advance its research and development process and expand its leading position in the field of tumor immunotherapy.

## Funding rounds

- Series A, Aug 21, 2025 — JC Capital, Yuanzhilifan Investment Management

## Investors

- JC Capital (https://capitalatlas.ai/funds/jc-capital) — Series A
- Yuanzhilifan Investment Management — Series A